about
Care of the dying patient: the last hours or days of lifeNSAIDs: gastroprotection or selective COX-2 inhibitor?Care of the dying: what a difference an LCP makes!The Association of Hydration Status with Physical Signs, Symptoms and Survival in Advanced Cancer-The Use of Bioelectrical Impedance Vector Analysis (BIVA) Technology to Evaluate Fluid Volume in Palliative Care: An Observational StudyEuthanasia and physician-assisted suicide: A white paper from the European Association for Palliative Care.The use of reflective diaries in end of life training programmes: a study exploring the impact of self-reflection on the participants in a volunteer training programme.Anti-Hu antibodies may indicate a positive response to chemotherapy in paraneoplastic syndrome secondary to small cell lung cancer.Identification of drug combinations administered by continuous subcutaneous infusion that require analysis for compatibility and stabilityLongitudinal bioimpedance assessments to evaluate hydration in POEMS syndrome.Educational interventions by pharmacists to patients with chronic pain: systematic review and meta-analysis.Have we drawn the wrong conclusions about the value of care pathways? Is a Cochrane review appropriate?Quality indicators for care of cancer patients in their last days of life: literature update and experts' evaluation.Benchmarking: a useful tool for informing and improving care of the dying?Research governance: impeding both research and teaching? A survey of impact on undergraduate research opportunities.Student-selected components in the undergraduate medical curriculum: a multi-institutional consensus on assessable key tasks.Respiratory tract secretions in the dying patient: a retrospective study.Patients' experience of cancer: evidence of the role of 'fighting' in collusive clinical communication.How well do we currently care for our dying patients in acute hospitals: the views of the bereaved relatives?
P50
Q24527232-A2173ED7-8294-42A3-A187-409884E9843BQ28168965-E3EF0612-A662-4D18-83C6-932651CEB63CQ28250980-99F99258-37B6-4F15-833B-864B8F36298DQ28554361-067088EE-E3D7-433C-A35E-E71D1237223CQ30381585-BDD4D4B6-8B8A-46D6-97CF-49712BBFA161Q30385290-A6E23A2B-34EA-4F4F-B002-E402D760719CQ35573954-8660F991-C994-46D1-8215-F34DA73984FFQ36321011-F6E5785A-F18E-49DB-BE60-544165B96051Q37235946-069F0433-7A45-4211-8335-F240488CBD48Q37879417-18F585C6-CDD9-43EE-9D6D-9B160BC53CF4Q37895009-06F67F2C-E33C-4E5D-862A-1F456ADBE0DDQ39653867-4DD586E0-8848-4AC1-BF7E-B71F4E8F0994Q40152385-0339F09C-B153-42B9-9E5F-00AB08B56903Q40188853-EED55F2A-6CB2-407E-9B54-96ED921BFA6DQ40353670-F2FB4726-DA5B-42DF-BFD4-F7632EFA643FQ40558046-81471222-F3F6-4414-B19E-0E82A3EC0031Q40634872-57F95F37-D6E9-477C-AA0D-835DFCCF01FEQ41543859-F8CFB0A0-4C82-4196-AA74-3BF4203DF406
P50
name
John Ellershaw
@ast
John Ellershaw
@en
John Ellershaw
@es
John Ellershaw
@nl
type
label
John Ellershaw
@ast
John Ellershaw
@en
John Ellershaw
@es
John Ellershaw
@nl
prefLabel
John Ellershaw
@ast
John Ellershaw
@en
John Ellershaw
@es
John Ellershaw
@nl
P1006
P214
P244
P1006
P21
P213
0000 0000 3839 3752
P214
P244
n2003145456
P31
P735
P7859
lccn-n2003145456